The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

NOVA2  -  neuro-oncological ventral antigen 2

Homo sapiens

Synonyms: ANOVA, Astrocytic NOVA1-like RNA-binding protein, NOVA3, Neuro-oncological ventral antigen 2, RNA-binding protein Nova-2
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NOVA2


Psychiatry related information on NOVA2

  • The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia [5].
  • ANOVA was used to compare the average time spent in moderate, hard, and very hard physical activities according to BMI status in boys and girls in grades 3, 7, and 11 [6].
  • RESULTS: Protocol 1: In the absence of esophageal acid, ketamine had no effect on either esophageal or foot pain thresholds (area-under-the-curve, [AUC] P = 0.36 esophagus, P = 0.34 foot, ANOVA) within 30 minutes of cessation of the infusion [7].
  • Adjusted Reelin-positive cell densities were also reduced in CA4 areas of subjects with bipolar disorder (ANOVA, P < 0.001) and nonsignificantly in those with major depression [8].
  • Although the mental health summary score declined significantly over time for the structured intermittent group, linear mixed modeling ANOVA indicated no significant difference across time for MOS-HIV summary and Symptom Distress Scale scores between the two treatment arms [9].

High impact information on NOVA2

  • Differences in total IL-8 release among groups approached statistical significance (ANOVA, p = 0.07) [10].
  • By two-factor ANOVA, E played the major role in preventing the increase in the bone resorption markers, whereas T had no significant effect [11].
  • During the 2-h SRIF infusion, insulin levels fell, and FFA levels rose from 474+/-22 to 1,042+/-116 micromol (P < 0.01); Mch-induced vasodilation was reduced by approximately 20% (P < 0.02, saline vs. SRIF, ANOVA) [12].
  • Mch-induced vasodilation relative to baseline was reduced by approximately 20% in response to the raised FFA levels in both groups (P < 0.05, saline vs. FFA, ANOVA) [12].
  • However, treatment of ECs with hypoxia-CM produced a threefold increase in 125I-VEGF binding, with peak at 24 h (P < 0.001, ANOVA) [13].

Chemical compound and disease context of NOVA2


Biological context of NOVA2


Anatomical context of NOVA2

  • pasilla, the Drosophila homologue of the human Nova-1 and Nova-2 proteins, is required for normal secretion in the salivary gland [3].
  • These features suggest an immune response against both Nova-1 and Nova-2 antigens throughout the central nervous system [22].
  • The intimal clearance of Lp(a) and LDL was similar and markedly increased in atherosclerotic compared with nonlesioned aortas (ANOVA, effect of atherosclerosis: P < 0.0001) [23].
  • Preoperative expression of HLA-DR epitopes on monocytes was significantly higher in patients given the study treatment (109% [95% CI 92-128]) than those given the control (69% [58-82]) compared with baseline (100%) (p=0.02, repeated measures ANOVA) [24].
  • Sumatriptan caused a significant reduction (p < 0.001 by ANOVA) in mean absolute coronary artery diameter, from 4.36 +/- 1.60 mm at baseline to 3.67 +/- 1.49 mm (16%) at 10 minutes and to 3.63 +/- 1.49 mm (17%) at 30 minutes after injection [25].

Associations of NOVA2 with chemical compounds

  • After the intravenous draflazine infusion, these values were 1.6 +/- 0.2 ml/100 ml forearm per min for placebo and 2.1 +/- 0.3, 3.3 +/- 0.6, 5.8 +/- 1.1, 6.9 +/- 1.4, 14.4 +/- 2.9, and 23.5 +/- 4.0 ml/100 ml forearm per min, respectively (Friedman ANOVA: P < 0.05 before vs after draflazine infusion) [26].
  • Over the total postinfusion period systolic and diastolic arterial pressure were 6 (SEM 2)% and 7 (2)%, respectively, higher than after dextrose infusion (ANOVA, p less than 0.001) [27].
  • Dividing the population into deciles according to total cholesterol and examining the categorical restenosis rate (by chi 2) as well as the absolute and relative loss by ANOVA again revealed no significant differences between deciles [28].
  • Flow-mediated dilation of the brachial artery (by ultrasonography) improved (all P<0.001 versus baseline values) on CE (4.0+/-2.6% to 10.2+/-3.9%), simvastatin (4.3+/-2.4% to 10.0+/-3.9%), and CE combined with simvastatin (4.6+/-2.0% to 9.8+/-2.6%), but similarly among therapies (P=0.507 by ANOVA) [29].
  • Group differences in peak exercise blood pressure in cocaine abusers with LVH, cocaine abusers without LVH, and control subjects were assessed by ANOVA [30].

Regulatory relationships of NOVA2

  • An ANOVA revealed medication (p<0.005) and deficit vs. nondeficit syndrome (p<0.05) as factors that influenced S100B significantly [31].
  • Loss of V1 receptor-stimulating activity and V2 receptor-stimulating activity was compared by two-way ANOVA [32].
  • Analysis of blood reticulocyte parameters by ANOVA in a randomized complete block design determined that anemia and EPO induced significant (P < or = 0.05) increases in red cell distribution width and reticulocyte mean cell volume [33].
  • Gender differences in the theta log power difference between alcoholics and controls were explored by using regional repeated-measures ANOVA [34].
  • Two-way ANOVA revealed that quinoa induced lower FFA levels with respect to GF pasta [35].

Other interactions of NOVA2

  • We have therefore named the gene ANOVA, for astrocytic NOVA1-like gene [1].
  • Significant heterogeneity in MLH1 focus frequency across donors was observed for larger chromosome arms (P<0.05, one-way ANOVA) [36].
  • DNA microarray hybridization showed a 3-fold induction of STC2 mRNA expression in MCF-7 cells in < or = 3 h of estrogen exposure and a 3-fold repression in the presence of antiestrogen (one-way ANOVA, P < 0.0005) [37].
  • ERRalpha mRNA was expressed at levels greater than or similar to ERalpha mRNA in 24% of unselected breast tumors, and generally at higher levels than ERalpha in the progesterone receptor (PgR)-negative tumor subgroup (1-way ANOVA with repeated measures, P = 0.030) [38].
  • An area under the curve (AUC(0-8h)) analysis for s-CTX after GLP-2 injection confirmed the dose-dependent decrease (ANOVA, p = 0.05) [39].

Analytical, diagnostic and therapeutic context of NOVA2

  • However, concentration of interleukin 6 was significantly lower in the treatment group (0.90 pg/L [0.69-1.18]) than in the control group (1.94 pg/L [1.45-2.59]) (p=0.032, repeated measures ANOVA) [24].
  • Multivariate ANOVA revealed a significant group effect (p < 0.001) in difference (vaccination minus baseline) values for percentage facial action, percentage cry time, and visual analogue scale pain scores [40].
  • A significant difference in percentage was observed between the intima area of allografts and that of syngrafts (P < .01, ANOVA) [41].
  • MaxFR was 2.13 +/- 0.53 after PTCA, elasticity 2.83 +/- 0.35 after stenting, and 2.73 +/- 0.58 at follow-up (ANOVA, P < .05) [42].
  • Arteries with AZ1-eluting stents had significantly less platelet deposition (15.8 +/- 4.5 x 10(7)) than either base-polymer (32.1 +/- 4.3 x 10(7)) or anti-CMV-eluting (35.2 +/- 8.8 x 10(7)) controls (ANOVA, P < .0001) [43].


  1. ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. Ueki, K., Ramaswamy, S., Billings, S.J., Mohrenweiser, H.W., Louis, D.N. Neurogenetics (1997) [Pubmed]
  2. Crystal structures of Nova-1 and Nova-2 K-homology RNA-binding domains. Lewis, H.A., Chen, H., Edo, C., Buckanovich, R.J., Yang, Y.Y., Musunuru, K., Zhong, R., Darnell, R.B., Burley, S.K. Structure (1999) [Pubmed]
  3. pasilla, the Drosophila homologue of the human Nova-1 and Nova-2 proteins, is required for normal secretion in the salivary gland. Seshaiah, P., Miller, B., Myat, M.M., Andrew, D.J. Dev. Biol. (2001) [Pubmed]
  4. Placental tissue interleukin-10 receptor distribution in pre-eclampsia. Hennessy, A., Painter, D.M., Orange, S., Horvath, J.S. Am. J. Reprod. Immunol. (2003) [Pubmed]
  5. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Yang, Y.Y., Yin, G.L., Darnell, R.B. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  6. Physical activity and body mass index in grade 3, 7, and 11 Nova Scotia students. Thompson, A.M., Campagna, P.D., Rehman, L.A., Murphy, R.J., Rasmussen, R.L., Ness, G.W. Medicine and science in sports and exercise. (2005) [Pubmed]
  7. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Willert, R.P., Woolf, C.J., Hobson, A.R., Delaney, C., Thompson, D.G., Aziz, Q. Gastroenterology (2004) [Pubmed]
  8. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Fatemi, S.H., Earle, J.A., McMenomy, T. Mol. Psychiatry (2000) [Pubmed]
  9. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection. Powers, A.E., Marden, S.F., McConnell, R., Leidy, N.K., Campbell, C.M., Soeken, K.L., Barker, C., Davey, R.T., Dybul, M.R. AIDS (2006) [Pubmed]
  10. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. Martich, G.D., Danner, R.L., Ceska, M., Suffredini, A.F. J. Exp. Med. (1991) [Pubmed]
  11. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. Falahati-Nini, A., Riggs, B.L., Atkinson, E.J., O'Fallon, W.M., Eastell, R., Khosla, S. J. Clin. Invest. (2000) [Pubmed]
  12. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. Steinberg, H.O., Tarshoby, M., Monestel, R., Hook, G., Cronin, J., Johnson, A., Bayazeed, B., Baron, A.D. J. Clin. Invest. (1997) [Pubmed]
  13. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. Brogi, E., Schatteman, G., Wu, T., Kim, E.A., Varticovski, L., Keyt, B., Isner, J.M. J. Clin. Invest. (1996) [Pubmed]
  14. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. Lee, K.O., Taylor, E.A., Oh, V.M., Cheah, J.S., Aw, S.E. Lancet (1991) [Pubmed]
  15. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Williams, S.B., Goldfine, A.B., Timimi, F.K., Ting, H.H., Roddy, M.A., Simonson, D.C., Creager, M.A. Circulation (1998) [Pubmed]
  16. Medial temporal lobe neuronal damage in temporal and extratemporal lesional epilepsy. Miller, S.P., Li, L.M., Cendes, F., Tasch, E., Andermann, F., Dubeau, F., Arnold, D.L. Neurology (2000) [Pubmed]
  17. Clinical studies with phenylpropanolamine: a metaanalysis. Greenway, F.L. Am. J. Clin. Nutr. (1992) [Pubmed]
  18. Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst-Eur Investigators. Staessen, J.A., Thijs, L., Mancia, G., Parati, G., O'Brien, E.T. Lancet (1994) [Pubmed]
  19. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Judd, L.M., Alderman, B.M., Howlett, M., Shulkes, A., Dow, C., Moverley, J., Grail, D., Jenkins, B.J., Ernst, M., Giraud, A.S. Gastroenterology (2004) [Pubmed]
  20. Non-invasive mapping of placental perfusion. Francis, S.T., Duncan, K.R., Moore, R.J., Baker, P.N., Johnson, I.R., Gowland, P.A. Lancet (1998) [Pubmed]
  21. Breastfeeding as prophylaxis against atopic disease: prospective follow-up study until 17 years old. Saarinen, U.M., Kajosaari, M. Lancet (1995) [Pubmed]
  22. Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma. Wirtz, P.W., Sillevis Smitt, P.A., Hoff, J.I., de Leeuw, B., Lammers, G.J., van Duinen, S.G., Verschuuren, J.J. J. Neurol. (2002) [Pubmed]
  23. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. Nielsen, L.B., Stender, S., Jauhiainen, M., Nordestgaard, B.G. J. Clin. Invest. (1996) [Pubmed]
  24. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Tepaske, R., Velthuis, H., Oudemans-van Straaten, H.M., Heisterkamp, S.H., van Deventer, S.J., Ince, C., Eÿsman, L., Kesecioglu, J. Lancet (2001) [Pubmed]
  25. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. MacIntyre, P.D., Bhargava, B., Hogg, K.J., Gemmill, J.D., Hillis, W.S. Circulation (1993) [Pubmed]
  26. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. Rongen, G.A., Smits, P., Ver Donck, K., Willemsen, J.J., De Abreu, R.A., Van Belle, H., Thien, T. J. Clin. Invest. (1995) [Pubmed]
  27. Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion. Blankestijn, P.J., Man in't Veld, A.J., Tulen, J., van den Meiracker, A.H., Boomsma, F., Moleman, P., Ritsema van Eck, H.J., Derkx, F.H., Mulder, P., Lamberts, S.J. Lancet (1988) [Pubmed]
  28. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Violaris, A.G., Melkert, R., Serruys, P.W. Circulation (1994) [Pubmed]
  29. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Koh, K.K., Cardillo, C., Bui, M.N., Hathaway, L., Csako, G., Waclawiw, M.A., Panza, J.A., Cannon, R.O. Circulation (1999) [Pubmed]
  30. Exaggerated pressor response to treadmill exercise in chronic cocaine abusers with left ventricular hypertrophy. Cigarroa, C.G., Boehrer, J.D., Brickner, M.E., Eichhorn, E.J., Grayburn, P.A. Circulation (1992) [Pubmed]
  31. Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schroeter, M.L., Abdul-Khaliq, H., Frühauf, S., Höhne, R., Schick, G., Diefenbacher, A., Blasig, I.E. Schizophr. Res. (2003) [Pubmed]
  32. Loss of biological activity of arginine vasopressin during its degradation by vasopressinase from pregnancy serum. Gordge, M.P., Williams, D.J., Huggett, N.J., Payne, N.N., Neild, G.H. Clin. Endocrinol. (Oxf) (1995) [Pubmed]
  33. Reticulocyte changes after experimental anemia and erythropoietin treatment of horses. Cooper, C., Sears, W., Bienzle, D. J. Appl. Physiol. (2005) [Pubmed]
  34. Theta power in the EEG of alcoholics. Rangaswamy, M., Porjesz, B., Chorlian, D.B., Choi, K., Jones, K.A., Wang, K., Rohrbaugh, J., O'Connor, S., Kuperman, S., Reich, T., Begleiter, H. Alcohol. Clin. Exp. Res. (2003) [Pubmed]
  35. In vitro starch digestibility and in vivo glucose response of gluten-free foods and their gluten counterparts. Berti, C., Riso, P., Monti, L.D., Porrini, M. European journal of nutrition. (2004) [Pubmed]
  36. Variation in MLH1 distribution in recombination maps for individual chromosomes from human males. Sun, F., Oliver-Bonet, M., Liehr, T., Starke, H., Turek, P., Ko, E., Rademaker, A., Martin, R.H. Hum. Mol. Genet. (2006) [Pubmed]
  37. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Bouras, T., Southey, M.C., Chang, A.C., Reddel, R.R., Willhite, D., Glynne, R., Henderson, M.A., Armes, J.E., Venter, D.J. Cancer Res. (2002) [Pubmed]
  38. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Ariazi, E.A., Clark, G.M., Mertz, J.E. Cancer Res. (2002) [Pubmed]
  39. Role of gastrointestinal hormones in postprandial reduction of bone resorption. Henriksen, D.B., Alexandersen, P., Bjarnason, N.H., Vilsbøll, T., Hartmann, B., Henriksen, E.E., Byrjalsen, I., Krarup, T., Holst, J.J., Christiansen, C. J. Bone Miner. Res. (2003) [Pubmed]
  40. Effect of neonatal circumcision on pain response during subsequent routine vaccination. Taddio, A., Katz, J., Ilersich, A.L., Koren, G. Lancet (1997) [Pubmed]
  41. Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Hirozane, T., Matsumori, A., Furukawa, Y., Sasayama, S. Circulation (1995) [Pubmed]
  42. Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis. Haude, M., Caspari, G., Baumgart, D., Brennecke, R., Meyer, J., Erbel, R. Circulation (1996) [Pubmed]
  43. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Aggarwal, R.K., Ireland, D.C., Azrin, M.A., Ezekowitz, M.D., de Bono, D.P., Gershlick, A.H. Circulation (1996) [Pubmed]
WikiGenes - Universities